Global Aminoglycosides Market By Type (Neomycin, Tobramycin, Gentamicin, Amikacin, and Other Types), By Application (Skin Infections, Respiratory Diseases, UTI & Pelvic Diseases, and Other Applications), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Aminoglycosides Market Overview:

Global aminoglycosides market sales were valued at over USD 3,140 million in 2021 & expected to register a CAGR of 4.6%.

This is due to the increasing prevalence of bacterial infection caused by both gram-positive as well as gram-negative bacteria. Utilization of these medications in the treatment of various bacterial contaminations in people as well as creatures because of the presence of attributes, for example, bactericidal, concentration-dependent killing activity, and action against staphylococci and certain mycobacteria is supposed to impact industry development.

Global Aminoglycosides Market Scope:

Type Analysis

In the product classification of aminoglycosides, streptomycin (neomycin), gentamicin (kanamycin), tobramycin, amikacin, and other antibacterial are all included. Streptomycin can be used to treat tuberculosis. MDR-TB is treated with aminoglycosides such as kanamycin capreomycin & amikacin.
Gentamicin is a popular choice for major and minor bacterial infections. Tobramycin was found to be somewhat less effective against Pseudomonas infections.

Amikacin or gentamicin can be used most often in veterinary medicine. After treatment with capreomycin fails, kanamycin should be used in MDR-TB. However, amikacin can be used to control kanamycin consumption. The effectiveness of amikacin at critical concentration was higher than that of kanamycin and capreomycin when tested against wild-type M. tuberculosis. It is also noted that the drug has a low minimum inhibitory dose (MIC) and is tolerable by pediatric patients.

A lack of quality assurance of active pharmaceutical ingredient (API) or WHO-GMP compliant products to capreomycin/kanamycin is a key factor that causes the sector to slow down in developing countries. Restricted market growth is expected due to a lack of supply from sources of capreomycin or kanamycin approved through WHO prequalification.

Application Analysis

The types of infections and the use of aminoglycosides can be classified as skin, respiratory, UTI, pelvic, neonatal, and veterinary. Because of the greater incidence of tuberculosis across developing regions, aminoglycosides were used to treat respiratory infections like tuberculosis. This was the largest share of the revenue for 2021. This segment is seeing an increase in multidrug-resistant tuberculosis cases. The forecast period will see an increase in the funding for international organizations engaged in the provision of subsidized treatment for tuberculosis. This is expected to boost demand for second-line drugs.

However, veterinary use of aminoglycosides is likely to slow down through 2022. This is due to the reduction of their usage in order to avoid side effects and resistance from food made from animals treated with aminoglycosides.

Key Market Segments:

By Type

• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Other Types

By Application

• Skin Infections
• Respiratory Diseases
• UTI & Pelvic Diseases
• Other Applications

Market Dynamics:

Increasing tuberculosis incidence will drive the demand for aminoglycosides. This is particularly true in low-income nations where the incidence is high and there is a great need for TB treatment regimens. The introduction of the digital health agenda by WHO (European Respiratory Society), for the eradication of tuberculosis, is expected to increase demand.

Global Drug Facility (UNITAID) and UNITAID, which act as an international intervention in tuberculosis diagnosis management, are expected to boost drug demand. The potential for this market to grow is anticipated by the presence of yearly procurement requirements by GDF or STOP TB Foundation, due to rising MDR-TB cases.

This industry is experiencing restricted growth due to the toxic effects of these drugs, including muscle twitching and irreversible hearing loss. Restrictive growth can also be attributed to a decrease in sales of aminoglycosides antibiotics, such as streptomycin, neomycin, or apramycin. The reduction in sales can be attributed to lower consumption of combinatorial drugs that include injectable and intramuscular aminoglycosides.

Regional Analysis

North America accounted for the largest portion of 2021 revenue with 45%. This is due to the higher incidence rate for multi-drug resistant tuberculosis (MDR) which requires second-line treatments. The large share of kanamycin/capreomycin in North America, along with the availability of other aminoglycosides, is attributable to the larger region.

Additionally, the potential market share for this region will be high due to the presence in India, China, Japan, and China of many market entities. Kanamycin is a major supplier to these regions, which in turn increases the industry’s revenue.

The U.S.’s inability to supply aminoglycosides such as kanamycin streptomycin and dilutomycin has contributed to a decrease in market revenue.

Variations in antibiotic resistance across different countries are partly responsible for different volumes, patterns, revenue generation, and consumption of aminoglycosides.

Key Regions and Countries covered in the report:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Market Share & Key Players Analysis:

The market is not available for some aminoglycoside antibiotics. New participants are expected to enter it; though regulatory approval is likely to hinder their entry. Manufacturers are expected to shift their focus to producing more viable alternatives to the drugs they currently have:

The following are leading key market players, among others.

Market Key Players:

• Kremoint Pharma Private Limited
• Medico Remedies
• Vega pharma
• Jiangxi bolai pharmacy co., ltd
• Huvepharma
• Medson Pharmaceuticals
• Hangzhou Uniwise International Co., Ltd
• Xi’an Wison Biological Technology
• Other Key Players

For the Global Aminoglycosides Market research study, the following years have been considered to estimate the market size: